skip to content


Issue No. 14 | March 28, 2008

News and Features

Spring 2008 Issue of Mental Health AIDS Released

Biopsychosocial therapy involves assessing an individual patient's biological, psychological, and social condition to help determine the best treatment.

Mental Health AIDS is a quarterly biopsychosocial research update on HIV and mental health sponsored by the Center for Mental Health Services (CMHS) of the Substance Abuse and Mental Health Services Administration (SAMHSA). This publication is provided free of charge through the SAMHSA Web site in both PDF and HTML formats.

The Spring 2008 issue features Part 2 of the "For Whom the Tell Tolls: Curbing the Cost of Giving & Getting Distressing, HIV-Related News" Tool Box. Part 1 addressed the terminology used to describe how clinicians are thought to be affected by their work with trauma survivors. Part 2 focuses on the current state of qualitative and quantitative research in this area and offers emerging evidence for the positive consequences of this work for clinicians.

More information is available:

Atazanavir Approved for Pediatric Use

On March 26, the FDA announced an update to the atazanavir label to include prescribing and adverse event information for pediatric patients between 6 and 18 years of age. Dosing is based on patient weight and should be boosted with ritonavir. Atazanavir is not recommended for patients less than 6 years of age, for patients less than 13 years of age without ritonavir boosting, or for patients with a body weight of less than 25 kg. Adverse events were similar to those of adult patients taking atazanavir, with the most common being an elevation in bilirubin levels in 49% of pediatric patients. These new recommendations are based on results from the pediatric clinical trial PACTG 1020A.

More information is available: